SUNDAY, JAN 15

Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology

National Doral, Miami, Florida 7:20 AM – 8:20 AM, Ballroom B



For more information about this no fee symposium visit **www.cmeoutfitters.com/PsA**



Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology

FACULTY

Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Professor of Medicine, Healthcare Policy and Research Weill Medical College of Cornell University Attending Rheumatologist Hospital for Special Surgery New York, NY

Leon H. Kircik, MD

Associate Clinical Professor of Dermatology Ichan School of Medicine at Mount Sinai New York, NY Associate Clinical Professor of Dermatology Indiana University Medical Center Indianapolis, IN Medical Director Physicians Skin Care, PLLC DermResearch, PLLC Louisville, KY

AGENDA

7:20AM - 7:25AM

Buffet Breakfast/Introductions

7:25AM - 7:30AM

Patient Story Presentation

7:30AM - 7:40AM

Simulation Module 1 Participation: Recognition, Referral, Diagnosis

7:40AM - 7:50AM

Faculty Discussion and Presentation of Evidence

7:50AM - 8:00AM

Simulation Module 2 Participation: Treatment

8:00AM - 8:10AM

Faculty Discussion and Presentation of Evidence

8:10_{AM} - 8:20_{AM}

Faculty Feedback and Q&A

#skinCME

Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology

LEARNING OBJECTIVE

- Implement appropriate, guideline-directed screening approaches in patients with psoriasis to facilitate a prompt diagnosis of PsA.
- Describe current treatment recommendations and emergent therapies for PsA.
- Strategize ways that specialists in rheumatology and dermatology can work together to improve detection and treatment of PsA.

The following learning objectives pertain only to those requesting CNE credit:

- Identify appropriate, guideline-directed screening approaches in patients to facilitate a prompt diagnosis of PsA.
- Describe current treatment recommendations and emergent therapies for PsA.
- Identify strategies that specialists in rheumatology and dermatology can use to work together to improve detection and treatment of PsA.

TARGET AUDIENCE

Rheumatologists, dermatologists, physician assistants, pharmacists, nurses, and other healthcare professionals with an interest in psoriatic arthritis.

COMMERCIAL SUPPORTER STATEMENT

Supported by an educational grant from Novartis Pharmaceuticals Corporation.



For more information about this no fee symposium visit www.CMEOutfitters.com/PsA

ACCREDITATION STATEMENTS

CME Credit: CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit: Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hour.

Note to Nurse Practitioners and Clinical Nurse **Specialists:** the content of this activity pertains to pharmacology. Earn up to 1.0 contact hour of pharmacotherapeutic contact hours.

CPE Credit: CME Outfitters, LLC, is accredited by the Accreditation Council Coun the Accreditation Council for Pharmacy pharmacy education. 1.0 contact hour (0.10 CEU)

Universal Activity Number: 0376-0000-17-004-L01-P

Type: knowledge-based

Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology



Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Weill Medical College of Cornell University Hospital for Special Surgery New York, NY

Biography

Dr. Gibofsky is Professor of Medicine, Healthcare Policy and Research at Weill Cornell Medicine and Adjunct Professor of Law at Fordham University

School of Law. He is an Attending Physician and Rheumatologist at New York Presbyterian Hospital and Hospital for Special Surgery, where he is Co-Director of the Clinic for Inflammatory Arthritis and Biologic Therapy.

Dr. Gibofsky received his undergraduate degree from Brooklyn College of the City University of New York, his MD from Weill Medical College of Cornell University and his law degree from Fordham University. He did his internship in Pathology, followed by a residency in Medicine at New York Hospital. He completed a fellowship in Rheumatology/Immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr. Gibofsky has authored or co-authored numerous papers and text chapters, primarily on the immunogenetics of rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular for his basic and clinical studies on rheumatic fever as well as for his work on therapeutic strategies in the treatment of inflammatory rheumatic diseases.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr. Gibofsky is Past-Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and received their Physician's Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees, and was Chair for Professional Education. Dr. Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He is a past president of the American College of Legal Medicine, and is past Chair of the American Board of Legal Medicine. In 2002, Dr. Gibofsky served as President of the American College of Rheumatology; in 2014, he was named a Master of the American College of Rheumatology.

Dr. Gibofsky is a Jonas Salk Scholar of the City University and in 1997, he was named Alumnus of the Year by Brooklyn College.

Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology



Leon H. Kircik, MD

Ichan School of Medicine at Mount Sinai, New York, NY

Indiana University Medical Center, Indianapolis, IN Physicians Skin Care, PLLC, Louisville, KY DermResearch, PLLC, Louisville, KY

Biography

Dr. Kircik is a Board Certified Dermatologist who graduated with AOA Honors from State University

of New York at the Health Sciences Center at Brooklyn after completing his undergraduate work with Phi Beta Kappa at New York University. He completed a Mohs Micrographic Surgery and Cutaneous Oncology Fellowship under the auspices of Dr. Frederick Mohs at the University of Wisconsin after completing his dermatology residency at State University of New York in Buffalo.

He currently teaches as Associate Clinical Professor of Dermatology at Indiana University Medical Center in Indianapolis, IN, as well as at Icahn School of Medicine at Mount Sinai Medical Center in New York City. Dr. Kircik is also the Medical Director of DermResearch, PLLC and Physicians Skin Care, PLLC in Louisville, Kentucky. He has been the principal investigator of numerous clinical trials for psoriasis, acne, rosacea, atopic dermatitis, skin cancers, and actinic keratosis, just to name a few.

Dr. Kircik is an author of many scientific articles, abstracts and posters. He has lectured extensively nationally and internationally on all aspects of dermatologic conditions. In addition, he also serves on the advisory boards of several pharmaceutical companies as a consultant. He is on the editorial board of *Journal of Drugs in Dermatology, Practical Dermatology, The Journal of Clinical & Aesthetic Dermatology*, and *Case Report in Clinical Pathology*. He volunteers for multiple local and national medical society committees.

Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology

DISCLOSURE DECLARATION

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky has disclosed that he serves on the speakers bureau for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB, Inc. He is a consultant for AbbVie; Amgen Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; and Pfizer Inc. He is a shareholder of AbbVie Inc.; Amgen Inc.; and Pfizer Inc.

Dr. Kircik has disclosed that he receives research/grants from Acambis; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Astellas Pharma US, Inc.; Asubio Pharma Co., Ltd.; Berlex Laboratories (Bayer HealthCare Pharmaceuticals); Biolife; Biopelle, Inc.; Boehringer-Ingleheim; Breckinridge Pharmaceutical, Inc.: Celgene Corporation; Centocor, Inc.; Coherus Biosciences; CollaGenex Pharmaceuticals; CombiMatrix; Coria Laboratories; Dermavant Labs; Dermiria, Inc.; Dow Pharmaceuticals Sciences, Inc.; DUSA Pharmaceuticals, Inc.; Eli Lilly and Company; Exeltis USA, Inc.; Ferndale Laboratories, Inc.; Galderma Laboratories, LP; Genentech, Inc.; GlaxoSmithKline, PLC; Health Point, LTD; Idera; Intendis, Inc.; Johnson & Johnson; LEO Pharma, Inc.; L?Oreal; 3M; Maruho Co., Ltd.; Merck & Co., Inc.; Medicis Pharmaceutical Corp.; NanoBio Corporation; Novartis AG; Noven Pharmaceuticals Corp.; Obagi Medical Products, Inc.; Onset; OrthoNeutrogena; Promius Pharma, LLC; PharmaDerm; Pfizer Inc.; Quatrix; SkinMedica, Inc.; Stiefel Laboratories, Inc.; Taro Pharmaceutical Industries, Ltd.; Tolerx, Inc.; UCB, Inc.; Valeant Pharmaceuticals Intl.; Warner-Chilcott; and XenoPort, Inc.

He serves on the speakers bureau for Abbott Laboratories; Allergan, Inc.; Amgen Inc.; Assos Pharmaceuticals; Astellas Pharma US, Inc.; Cipher Pharmaceuticals US LLC; Connectics Corporation; Dermik Laboratories; Embil Pharmaceuticals; Exeltis, USA, Inc.; Galderma Laboratories, LP; Genentech, Inc.; Innocutis Medical, LLC; Innovail; Johnson & Johnson; LEO Pharma, Inc.; L?Oreal; 3M; Onset; OrthoNeutrogena; PediaPharma; PharmaDerm; Serono (Merck Serono International SA); SkinMedica, Inc.; Stiefel Laboratories, Inc.; Sun Pharma; Taro Pharmaceutical Industries Ltd.; Triax Pharmaceuticals; UCB, Inc.; Valeant Pharmaceuticals Intl.; and Warner-Chilcott.

Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology

He serves on the advisory board for Aclaris Therapeutics, Inc.; Allergan, Inc.; Almirall; Anacor Pharmaceuticals, Inc.; Biogen Idec; Colbar; Celgene Corporation; Cipher Pharmaceuticals US LLC; Connectics Corporation; EOS; Exeltis, USA, Inc.; Ferndale Laboratories, Inc.; Galderma Laboratories, LP; Genentech, Inc.; Intendis, Inc.; Innocutis Medical, LLC; ISDIN; Johnson & Johnson, NanoBio Corporation; OrthoNeutrogena; Promius Pharma, LLC; Quinnova Pharmaceuticals; SkinMedica, Inc.; Stiefel Laboratories, Inc.; Sun Pharma; Valeant Pharmaceuticals, Intl.; and Warner-Chilcott.

He serves as a consultant for Allergan, Inc.; Almirall; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Colbar; Cipher Pharmaceuticals US LLC; CollaGenex Pharmaceuticals; Connetics Corporation; Exeltis USA, Inc.; Galderma Laboratories, LP; Genentech, Inc.; Intendis, Inc.; ISDIN; Johnson & Johnson; Laboratory Skin Care Inc.; LEO Pharma, Inc.; Medical International Technologies; Merck & Co., Inc.; Merz, Inc.; Novartis AG; OrthoNeutrogena; Promius Pharma, LLC; PuraCap Pharmaceutical LLC; SkinMedica, Inc.; Stiefel Laboratories, Inc.; Taro Pharmaceutical Industries, Ltd.; UCB, Inc.; Valeant Pharmaceuticals Intl; and ZAGE.

Erica Perilstein, MD (peer review) has no disclosures to report.

Naomi Wong, RMA (peer review) has no disclosures to report.

Daniela V. DiBiase, MS (planning committee) has no disclosures to report.

Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

Jan Perez, CHCP (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis

Bridging Rheumatology and Dermatology

INSTRUCTIONS FOR INTERACTIVE TECHNOLOGY

If you would like to use your tablet or mobile device to answer polling questions, view the onsite presentations, and submit questions to the faculty, please follow the instructions below:

1. Get Connected

- Please connect to the **CME Outfitters network** with your mobile device or laptop. This network does not have a password.
 - * Please note that this network is a local network and does NOT mean you're connected to the internet.
- Once you have joined the network, go to arraylearn.com
- You are now connected to the symposium. All content and polling questions can be viewed on your device as long as you are connected to the above listed network.

2. Ask a Question to the Faculty

Please click on "Ask a Question" and type your question. Please include
the faculty member's name if the question is specifically for them. Your
question will be sent to the faculty for the question and answer portion
of the session.

3. View and Take Notes on Presentation Slides

 Please click on the "Take a Slide Note" button. If you did not enter your email address when you joined the meeting, you will be required to do so for note taking. When the meeting is complete, all your notes will be emailed to you within 5 business days.

OBTAINING CREDIT

In order to receive credit, please complete the evaluation/test form found on your table and turn them in to the CME Outfitters staff on your way out.

PRESENTATION SLIDES

Downloadable resources will be available at www.CMEOutfitters.com/PsAresources



More Available Activities from CME Outfitters:



Check out a full list of activities on www.cmeoutfitters.com

Meeting Highlights from a National Dermatology Conference

In this CME Outfitters Snack and Meeting Highlights series, expert faculty translate insights and recommendations from a national dermatology and psoriasis conference in Las Vegas, NV about current and emerging psoriasis treatment, monitoring of patients on biologics, management of comorbidities, and quality of life.

Visit www.CMEOutfitters.com/CM20066 to participate.

The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis

In this CME Outfitters decision-tree medical simulation participants will navigate the clinical challenges presented by a patient with RA. Along the way, expert faculty will provide guidance, insights, and evidence for the positive and negative consequences of their decisions. This actionable, evidence-based simulation and improve clinician confidence in their ability to recognize and assess comorbidities, improve coordination of care among health care providers, and develop personalized treatment plans for managing comorbid conditions in patients with RA.

Visit www.CMEOutfitters.com/CM20149 to participate.

Treating to Target in Patients with Gout and Chronic Kidney Disease

Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

Visit www.CMEOutfitters.com/CM20163 to participate.

Optimizing Care in IBD: Evidence, Cost, and Patient Goals

In this CME Outfitters Live and On Demand, expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.

Visit www.CMEOutfitters.com/CM20151 to participate.